What is it about?
This review article demonstrates that t-MDS is more similar to de novo MDS than t-AML, and its prognosis should be obtained from the same parameter of de novo MDS. Cytogenetics and mutations are qualitatively the same, but the high-risk mutations and cytogenetics are more frequent in t-MDS.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
The conclusion of this review article is in line with the new classification of myeloid neoplasm, which abolishes the group of therapy-related myeloid neoplasm, including AML and MDS.
Perspectives

At present the diagnosis of therapy-related MDS is based only on the history of the patient, some other parameter should be added, like some mutations more frequent in the therapy-related.
Prof. Giuseppe Leone
Universita Cattolica del Sacro Cuore
Read the Original
This page is a summary of: DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES, Mediterranean Journal of Hematology and Infectious Diseases, April 2022, Institute of Hematology, Catholic University,
DOI: 10.4084/mjhid.2022.030.
You can read the full text:
Contributors
The following have contributed to this page